FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
This article was originally published in The Pink Sheet Daily
Executive Summary
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.
You may also be interested in...
Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market
In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications
Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market
In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications
Shire Takes The Route Of Least Resistance Into Europe With Approved Oral ADHD Drug
Specialty pharma withdraws marketing application for Noven’s Daytrana patch after regulators request European study, sticks with in-licensed oral drug that’s already approved.